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Chapter 1 Introduction 
Urate is a weak organic acid with a pKa value of 5.8. It is the end product of 
purine degradation in humans and some higher primates. Due to the mutation 
of urate oxidase gene occurred in Miocene epoch [1-3], urate in humans 
cannot undergo further oxidation catalyzed by urate oxidase (UOX1 or uricase) 
to form allantoin, a more water-soluble substance with being easily excreted. 
Loss of urate oxidase results in higher serum urate level (SUA) in humans, 
compared with those in other mammals [4-5]. Mutation of urate oxidase and 
increased serum urate level were believed to be of critical importance in 
creating human by working as a cerebral stimulant to accelerate brain 
development and improve human intelligence because of the similarities of 
urate to other cerebral stimulants, such as caffeine or theobromine [6]. Urate 
also has strong antioxidant properties and helps humans survive in the oxygen 
environment by cleaning oxidants, such as singlet oxygen and hydroperoxyl 
radicals, which are harmful to humans. It is reported that urate eliminates 
about as much as 60% of free radicals in human serum [7-9]. Increased serum 
urate level owing to evolutionary loss of uricase in humans is regarded as 
compensation to the mutation of L-gulonolactone oxidase, which is responsible 
for the synthesis of another important antioxidant substance, vitamin C [10-13]. 
In addition to its antioxidant function, urate seems to play a pivotal role in the 
maintenance of in vivo blood pressure homeostasis in humans [14, 15].    
 
Epidemiologic studies show that abnormal serum urate level is associated with 
several diseases. For example, hyperuricemia is closely related to gout attack, 
a disease with a history of more than 5,000 years ever since its first 
documentation in Egypt [16]. Gout is featured by the accumulation of 
monosodium urate (MSU) monohydrate crystals in joints [17-20]. Urate 
crystals deposited in joint lead to inflammation responsive via activating 
NLRP3 inflammasome [20]. Hyperuricemia (serum urate level over 420 μM for 
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men, over 360 μM for women) may increase the risk of gout attack as reported 
by many studies [21-24]. Previous reports also indicate that hyperuricemia 
might play a role in the development of coronary heart disease, stroke, 
hypertension, diabetes mellitus, renal diseases and other cardiovascular 
diseases [25-42]. Because urate has anti-oxidant property, reduced SUA level 
may cause harmful effect in humans. Reduced serum urate level may 
decrease the antioxidant ability of humans. Indeed, hypouricemia (serum urate 
level lower than 120 μM) has already been linked to Hodgkin’s disease and 
Alzheimer’s disease [43-46]. Thus, maintenance of normal serum urate level is 
crucial to human health. Due to the close relationship of urate with a number of 
diseases, it has been used as a biomarker for many diseases [47-50] and is 
now involved in regular clinical blood test. Clinical and animal studies have 
suggested the participation of urate in the generation and development of 
diseases, and the importance of controlling urate level as a preventing and/or 
treating method of such diseases as well [45].  
 
Generation of urate primarily occurs in liver, muscles and intestine, while 
excretion of urate mainly occurs from the kidney and intestine [51-52]. Of the 
urate daily produced, about two thirds is excreted from kidney and the rest is 
mainly eliminated directly across intestinal epithelial cells from blood [52-53]. 
In kidney, there is a urate transport system located on renal proximal tubule 
which plays an important role in the regulation of serum urate level. Most of 
urate is filtrated at the glomerulus and reabsorbed by this transport system. In 
2002, Enomoto et al. identified human urate transporter 1 (URAT1, encoded by 
SLC22A12) as a reabsorptive urate transporter on the apical membrane of 
renal proximal tubule where it plays a predominant role in urate uptake from 
urine [54]. Mutations and defects of human URAT1 have been reported to 
result in hypouricemia [55-57]. Previous studies found that many drugs (such 
as benzbromarone and losartan) could decrease serum urate level by 
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exhibiting inhibitory effects on URAT1 [58-60]. These studies have suggested 
an essential role of URAT1 in the transport of urate.  
 
Similarly, organic onion transporter 4 (OAT4, encoded by SLC22A11) and 
OAT10, encoded by SLC22A13, are highly expressed at the apical side of 
proximal tubular cells and also involved in the reabsorptive transport of urate 
from luminal side into tubular cells [61-63]. On the basolateral membranes of 
proximal tubular cell, a voltage-driven urate transporter, URATv1 (GLUT9) 
encoded by SLC2A9 gene is recently reported as a solute carrier responsible 
for the urate transport from the tubular cells into blood [64]. Hypouricemia was 
also found in patients with the loss-of-function mutations in URATv1, 
independent of genetics of URAT1 [64]. URAT1, OAT4, and OAT10 at the 
apical side of renal proximal tubule and URATv1 at the basolateral side of 
proximal tubule cells together consist of the vectorial transport form the urine 
to blood (as is shown in Fig. 1-1).  
 
Since urate simultaneously undergoes secretion from blood to urine, other 
transporter system may also important to consider renal handling of urate in 
kidney. The system is possibly consisted of organic onion transporter 1 (OAT1, 
encoded by SLC22A6), and organic onion transporter 3 (OAT1, encoded by 
SLC22A8) on the basolateral side of proximal tubule cells, and sodium 
phosphate transporter 1 (NPT1, encoded by SLC17A1), NPT4 (encoded by 
SLC17A3), multidrug resistance protein 4 (MRP4, encoded by ABCC4), and 
breast cancer resistance protein (BCRP, encoded by ABCG2) [65-74].  
 
Serum urate level is also influenced by non-renal urate transport pathway. In 
humans, expression of BCRP in kidney is relatively low compared with other 
organs [73]. On the contrary, expression of BCRP in intestine is high where 
one third of urate daily generated is excreted, compared with the expression in 
kidney. BCRP is expressed at the apical side of intestinal epithelial cells and 
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mediates the urate efflux transport across the intestinal epithelial wall. 
Reduction of BCRP function is closely related to gout and hyperuricemia as is 
demonstrated by recent genome-wide association studies [75-76]. Thus, 
BCRP can be regarded as an important efflux transporter mediating the 
non-renal excretion of urate (as is shown in Fig. 1-2).    
 
With the development of economy, and westernization of lifestyle, the past 
several decades have witnessed an obvious increase in the prevalence of 
diseases such as cardiovascular disease, obesity, hyperuricemia, diabetes 
mellitus, which are called “rich man’s diseases” and the prevalence of these 
disease will continue to increase in the following several decades [77-79]. 
Serum urate level seems to be closely associated with these diseases [80]. 
Due to the important role of urate transporters in regulation serum urate level, 
modulation of these urate transporters to control serum urate level is of critical 
significance. The present thesis will focus on this topic and investigate the 
modulation of urate transporters to affect serum urate level.  
 
Fig. 1-1 Transporter mediated urate transport in renal proximal tubule. On the 
apical side of renal proximal tubule, URAT1, OAT4, and OAT10 are 
responsible for the reabsorptive transport of urate from luminal side into renal 














proximal tubular cell. On the basolateral side, URATv1 is responsible for the 
transport of urate from proximal tubular cell into blood. OAT1 and OAT3 on the 
basolateral side mediate the urate excretory transport from blood into proximal 
tubular cell. MRP4, BCRP, NPT1 and NPT4 located on the apical side 
functions as excretory transporter and transport urate from proximal tubular 
cell into urine.  
 
 
Fig. 1-2 Transporter mediated urate transport in intestine. BCRP is located at 
the apical side of intestinal epithelial cells and responsible for the urate efflux 
transport into intestinal lumen. 
 








Chapter 2 Functional cooperation of SMCTs and 
URAT1 for renal reabsorption transport of urate  
Abstract: 
Urate is mainly excreted into urine in humans. Serum urate level is regulated 
by a urate transport system located on renal proximal tubule. Urate transporter 
1 (URAT1) is located on the apical side of renal proximal tubule and is 
responsible for the reabsorption of urate from luminal side into tubular cells. At 
the same site, it has been hypothesized that sodium-coupled monocarboxylate 
transporters (SMCTs) are responsible for the transportation of 
monocarboxylates such as lactate and nicotinate, which are exchanged for 
urate transport via URAT1 as the driving force. Accordingly, SMCTs could 
indirectly stimulate URAT1-mediated urate reabsorption by providing a counter 
ion, monocarboxylates, for the exchange.  
The present study investigated to clarify the hypothesized functional 
cooperative relationship between URAT1 and SMCTs in the reabsorptive 
transport of urate. By preloading nicotinate in SMCT1-URAT1 co-expressing 
Xenopus oocytes, URAT1-mediated urate transport was stimulated by 
preloading nicotinate. Nicotinate was taken up by SMCT1 but not by URAT1. 
When removing sodium ion from the uptake medium, the stimulation effect 
was decreased. When adding SMCT1 inhibitors, the stimulation effect was 
also reduced. The results from this study indicate the cooperative relationship 
of URAT1 and SMCT1, and that SMCT1 is a potential target for the alteration 





Renal urate transport system is essential to the regulation of serum urate level. 
In kidney, many urate transporters including URAT1 are involved in renal 
handling of urate. Monocarboxylates are the counterpart of urate in the 
transport of urate via URAT1. Recently, two members of sodium-coupled 
monocarboxylate transporters were identified and characterized as 
monocarboxylate transporters with electrogenic nature, in which SMCT1 and 
SMCT2 were encoded by SLC5A8 and SLC5A12, respectively [81-82]. 
Substrates of SMCT1 and SMCT2 include lactate, nicotinate, and butyrate 
[81-82]. Both of them are reported to locate on the apical side of proximal 
tubular cells [81-82]. SMCTs are involved in the absorption of 
monocarboxylates in a sodium-dependent manner, and it is hypothesized that 
SMCTs enhance URAT1-mediated urate reabsorption by providing 
monocarboxylates for the exchange transport with urate. Moreover, 
Thangaraju et al. observed the decrease of serum urate level and increase of 
urinary excretion of urate in mice that are knocked out of both Slc5a8 and 
Slc5a12 in the kidney [83]. Serum lactate level was also reduced in the 
knockout mice. These observations indicated a possible role of SMCT1 and 
SMCT2 in the reabsorptive transport of urate in kidney. Accordingly, it is 
considered that URAT1 and SMCTs are linked via lactate and/or other 
monocarboxylates transport [84-86]. Furthermore, it has been reported that 
PDZK1, which is a PDZ domain containing protein located on the renal 
proximal tubule, could bind to URAT1 at the C terminal part of URAT1 [87]. In 
addition, SMCT1 and SMCT2 were reported to be binding partners of PDZK1 
[84]. These findings suggested possible physiological links between URAT1 
and SMCTs in the renal reabsorption of urate in renal proximal tubule. 
However, to date there is no direct functional evidence to show the cooperative 
relationship of URAT1 and SMCTs in urate transport. Collectively, it is thought 
that SMCTs and URAT1 have a cooperative relationship in urate transport; 
therefore, we designed the current study and investigated the cooperative 
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relationship between SMCTs and URAT1 using the Xenopus oocytes 
gene-expressing system. The results of this study provide strong support for 
the functional links of SMCTs and URAT1 in the transport of urate.  
   
Fig. 2-1 Hypothesized urate transport model at renal proximal tubule. SMCTs 
take up monocarboxylates, such as lactate and nicotinate, from luminal side 
into proximal tubular cells. The monocarboxylates taken up by SMCTs then 
















2-2 Materials and Methods 
2-2-1 Chemicals and reagents 
[14C]Urate (1.96 TBq/mol) was obtained from Moravek Biochemicals, Inc. 
(Brea, CA). [3H]Nicotinate (37 GBq/mol) was purchased from American 
Radiolabeled Chemicals Inc. (St. Louis, MO). Nicotinate (purity>98%), 
collagenase and gentamicin sulfate were purchased from Wako Pure 
Chemical Industries (Osaka, Japan). Sodium L-lactate (purity around 98%), 
sodium butyrate (purity>98.5%), N-methyl-D-glucamine (NMDG) and 
phenol/chloroform/isoamyl alcohol (25:24:1) were the products of 
Sigma-Aldrich (St. Louis, MO). Clearsol-I was obtained from Nacalai Tesque 
(Kyoto, Japan). All other reagents were of analytical grade.   
 
2-2-2 Preparation of human URAT1 and SMCT1 cRNA 
Human URAT1 plasmid DNA, which was cloned in pGEMHE vector, was 
synthesized according to the method previously described [88] and then the 
plasmid DNA was digested with NheI (Takara Bio Inc., Otsu, Japan) before 
cRNA preparation. SMCT1 plasmid DNA cloned in pGH19 vector [81] was 
kindly provided by Professor Seiji Miyauchi at Toho University and was 
linearized by PstI (Takara Bio Inc., Otsu, Japan). cRNA of URAT1 and SMCT1 
were synthesized by in vitro transcription method using T7 
mMESSAGE-mMACHINE kit (Ambion, Austin, TX). One μg of the linearized 
template DNA was mixed with 10 μL of 2X NTP/CAP, 2 μL of 10X Reaction 
Buffer, 2 μL Enzyme Mix supplemented with purified water to 20 μL, and 
incubated in a water bath maintained at 37 oC for 2h. Then, 1 μL of TURBO 
DNase was added to the reaction tube and the tube was incubated at 37 °C for 
15 min. After that, 115 μL of pure water and 15 μL of ammonium acetate stop 
solution were added, and mixed thoroughly. 150 μL of phenol/chloroform/ 
isoamyl alcohol (25:24:1) was added to extract RNA. After centrifuged at 
15,000 rpm for 15 min (4 °C), the aqueous phase (upper phase) of the sample 
was transferred into another tube. Sample was then added with an equal 
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volume of chloroform, vortexed for 2min, and centrifuged at 15,000 rpm for 15 
min (4 °C). The aqueous phase (upper phase) of the sample was transferred 
into another tube. RNA was precipitated by the addition of an equal volume of 
isopropanol and chilled at –20 °C overnight. Pellet of RNA was obtained by 
centrifuging the sample at 15,000 rpm for 20 min (4 °C). RNA pellet was then 
washed by the addition of 100 μL of 70% ethyl alcohol and dried in a water 
bath maintained at 37°C for 1 h to evaporate residual ethyl alcohol. RNA was 
dissolved in purified water. Concentration of RNA was determined by UV 
method on an Eppeendorf BioPhotometer (Eppendorf, Hamburg, Germany).  
 
2-2-3 Preparation of Xenopus oocytes 
Xenopus laevis provided by Hamamatsu Biological Research Service, Inc. 
(Hamamatsu, Japan) were anaesthetized for 30 min in a mixture of ice and 
water. Then Xenopus laevis were put on ice and oocytes were taken out from 
ovaries of Xenopus laevis. After washed by Oocyte Ringer 2 (OR2) solutions 
10 times, oocytes were incubated with 2 mg/mL collagenase (dissolved in OR2 
solution) for up to 20 min at room temperature. Then oocytes were washed by 
pH7.4 OR2 solution another 10 times and were transferred into a dish 
containing the modified Barth solution (MBS, pH7.4) supplemented with 50 
μg/mL gentamycin. Oocytes were defolliculated with fine forceps under 
Olympus SZ61 stereo microscope (Olympus Optical Co. Ltd., Tokyo, Japan) 
before use. Defolliculation of the oocytes was carried out in pH7.4 
Defolliculation solution.  
 
Oocyte Ringer 2 (OR2) solution:  
82.5 mM NaCl 
2 mM KCl 
10 mM MgCl2  
5 mM HEPES 




Modified Barth’s solution (MBS): 
88 mM NaCl 
1 mM KCl 
0.33 mM Ca(NO3)2  
0.41 mM CaCl2 
0.82 mM MgSO4 
2.4 mM NaHCO3 
10 mM HEPES 
Adjust pH to 7.4. 
 
Defolliculation solution 
110 mM NaCl 
1 mM EDTA*2Na 
10 mM HEPES 
Adjust pH to 7.4. 
       
2-2-4 Expression of URAT1 and SMCT1 protein in Xenopus laevis 
oocytes 
URAT1 and SMCT1 protein were expressed in Xenopus oocytes by 
microinjection method. In preparing oocytes expressing URAT1 alone, 12.5 ng 
URAT1 cRNA (50 nL) was injected into each oocyte by a Drummond Digital 
Microdispenser (Drummond Scientific Company; Broomall, PA, USA). In 
oocytes expressing both URAT1 and SMCT1, a 50 nL mixture of 12.5 ng 
URAT1 cRNA and 12.5 ng SMCT1 cRNA was injected into each oocyte. The 
rest of the oocytes were injected the same volume of water as background. 
After microinjection, Xenopus oocytes were cultured in MBS containing 50 
μg/mL gentamycin for 2-3 days at 18 oC before the uptake experiment. All 
experiments concerning Xenopus laevis were carried out according to the 
guiding principles promulgated by the Institutional Animal Care and Use 
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Committee of Kanazawa University.  
 
2-2-5 Uptake study by Xenopus laevis oocyte 
For urate uptake experiments, oocytes were preloaded with monocarboxylate 
by preincubation for 60 min or the indicated time in each result at 25 oC in 
ND96 buffer in the presence or absence of sodium ions (in the study 
investigating sodium effect, sodium ions were substituted by NMDG) 
containing monocarboxylate before urate uptake. Then, the oocytes were 
washed three times with 25oC ND96 buffer in the presence or absence of 
sodium ions. The uptake study was carried out for 60 min at 25 oC in ND96 
buffer in the presence or absence of sodium ions containing 10 μM [14C]urate.  
For nicotinate uptake experiments, the uptake study was carried out at 25 oC in 
ND96 buffer containing radio-labeled and unlabeled nicotinate and was 
stopped by removing the uptake buffer, and then the oocytes were washed 
three times with ice-cold uptake buffer. Each oocyte was transferred into a 
microcentrifuge tube containing 50 μL 5% sodium dodecyl sulfate solution. 
After homogenization of the oocytes, 1.5 mL of Clearsol-I was added into each 
tube for quantitation of radioactivity.  
 
Uptake buffer used in this study: 
pH 7.4 ND96 buffer: 
96 mM NaCl 
2 mM KCl 
1 mM MgCl2 
5 mM HEPES 
Adjust pH to 7.4.  
 
ND96 buffer free of sodium ions: 
192 mM N-methyl-D-glucamine  
plus 19.2 mL 5N HCl 
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3.6 mM CaCl2 
4 mM KCl 
2 mM MgCl2 
10 mM HEPES 
Adjust pH to 7.4 
 
2-2-6 Analytical method 
A liquid scintillation counter (LSC-5100, Aloka, Tokyo) was used to determine 
the radioactivity. The amount of [14C]urate or [3H]nicotinate taken up by 
oocytes was calculated according to the radioactivity obtained from each 
oocyte. Uptake of urate or nicotinate, expressed as the cell-to-medium (C/M) 
ratio (μL/oocyte), was calculated by dividing the uptake amount by the 
concentration of substrate in the uptake buffer. Results were expressed as 
mean ± SEM. Statistical differences were analyzed by Student’s t-test. A p 





2-3-1 Effect of lactate on URAT1-mediated urate uptake  
Initially, urate uptake by oocytes expressing URAT1 alone or SMCT1-URAT1 
co-expressing oocytes was determined after preloading 1.5 mM L-lactate for 
60 min before urate uptake, respectively. The result is shown in Fig. 2-2. Urate 
uptake by oocytes expressing both SMCT1 and URAT1 was higher than that 
by oocytes expressing URAT1 alone, as shown in Fig. 2-2. The increase of 
urate uptake can be attributable to two mechanisms. Firstly, the L-lactate taken 
up by SMCT1 can be high enough to be exchanged with urate and enhance 
the urate uptake. The second is due to the different expression level of URAT1 
between oocytes expressing URAT1 alone and both of SMCT1 and URAT1. 
The former mechanism, which is a hypothesis of the present study, was further 
examined.  
 
Fig. 2-2 Stimulation effect of monocarboxylate on urate uptake. 
SMCT-URAT1 co-expressing oocytes (closed bar), oocytes expressing URAT1 
alone (open bar) and water-injected oocytes (slashed bar) were preincubated 
in ND96 buffer (pH7.4) containing 1.5 mM sodium lactate for 60 min. Then, the 























min. Each point represents the mean ± SEM from 9-10 oocytes. Student’s 




2-3-2 Effect of different monocarboxylates on URAT1-mediated urate 
uptake in Xenopus oocytes expressing both SMCT1 and URAT1 
In order to eliminate the differences of uptakes caused by the difference of 
expression level of transporter proteins between URAT1-alone and 
SMCT1-URAT1 double expressing oocytes, and to optimize condition for this 
study, the effect of several other monocarboxylates on urate uptake was 
examined in SMCT1-URAT1 co-expressing oocytes. Nicotinate, butyrate, and 
L-lactate were used as monocarboxylates to examine the stimulation effect of 
urate transport by URAT1. The results are shown in Fig. 2-3. SMCT1-URAT1 
co-expressing oocytes were preincubated with 1.5 mM nicotinate, butyrate, or 
L-lactate for 60 min before initiation of urate uptake. Then, uptake of urate by 
SMCT1-URAT1 co-expressing oocytes was measured for 60 min at 25 oC in 
ND96 buffer containing 10 μM [14C]urate. Nicotinate and L-lactate exhibited a 
stimulation effect on urate uptake. Nicotinate exhibited the highest stimulation 
effect of the urate uptake, which was as much as 8.7 folds compared with the 
control (SMCT1-URAT1 co-expressing oocytes without preloading of 
nicotinate) group. L-Lactate also exhibited a stimulation effect with an increase 
of 28% compared with control group. As for butyrate, although it tends to 
stimulate (22%), there was no statistically significant difference compared with 





Fig. 2-3 Effect of different monocarboxylates on urate uptake by 
SMCT1-URAT1 co-expressing oocytes. SMCT1-URAT1 co-expressing 
oocytes (closed bar) and water-injected oocyte (open bar) were preincubated 
in ND96 buffer (pH7.4 containing 1.5 mM sodium nicotinate, sodium butyrate, 
or sodium lactate at 25oC for 60 min before urate uptake. Then, the oocytes 
were washed three times with ND96 buffer (pH7.4) and were transferred to a 
24-well plate containing ND96 buffer (pH7.4) and 10 μM [14C]urate for the 
uptake study. Each point represents the mean ± SEM from 8-9 oocytes. 
Student’s t-test: ***p<0.001, *p<0.05, compared with control.  

























2-3-3 Accumulation of nicotinate by Xenopus oocytes co-expressing 
SMCT1 and URAT1 
Fig. 2-4 depicts the accumulation of nicotinate in oocytes co-expressing 
SMCT1-URAT1 and oocytes expressing URAT1 alone. When the uptake time 
was set at 60 min, accumulation of nicotinate in SMCT1-URAT1 co-expressing 
oocytes exhibited a concentration-dependence and saturated at 1 mM (Km: 
241 ± 36 μM) (Fig. 2-4A). When nicotinate concentration was set at 1 mM, 
accumulation of nicotinate in SMCT1-URAT1 co-expressing oocytes reached 
steady-state at 60 min (Fig. 2-4B). In oocytes expressing URAT1 alone, the 
accumulation of nicotinate is quite small compared with that of SMCT1-URAT1 
co-expressing oocytes and was comparable with that in water-injected control 
oocytes.  
 
Fig. 2-4 Accumulation of nicotinate in oocytes expressing SMCT1 and URAT1. 
A. Uptake of nicotinate was investigated in SMCT1-URAT1 co-expressing 
oocytes (closed circle), oocytes expressing URAT1 alone (open circle), or 


























from 0.15 to 1.5 mM. The uptake time was set at 60 min. Each point represents 
the mean ± SEM from 9-10 oocytes. 
 
 
B. Uptake of nicotinate was investigated in SMCT1-URAT1 co-expressing 
oocytes (closed circle), oocytes expressing URAT1 alone (open circle), or 
water-injected oocytes (closed triangle) with uptake time ranged from 15 to 90 
min. Nicotinate concentration was set at 1 mM. Each point represents the 

























2-3-4 Influence of preincubation concentration of nicotinate on its 
stimulation effect of URAT1-mediated urate uptake 
Influence of nicotinate concentration on the stimulation effect was studied in 
SMCT1-URAT1 co-expressing oocytes after preloading 0, 0.15, 0.5, and 1 mM 
nicotinate for 60 min. Urate uptake was stimulated by nicotinate in 
SMCT1-URAT1 co-expressing oocytes in a concentration-dependent manner 
(Fig. 2-5A). Effect of preloading of nicotinate on urate uptake by oocytes 
expressing URAT1 alone was also studied. An increase of urate uptake by 
URAT1 expressing oocytes was also observed after preloading nicotinate 
compared without preloading of nicotinate. Accordingly, co-expression of 




Fig. 2-5 Influence of preincubation time and concentration of nicotinate on the 
stimulation of urate uptake by SMCT1-URAT1 co-expressing oocytes. 
A. SMCT1-URAT1 co-expressing oocytes (closed circle), oocytes expressing 
URAT1 alone (open circle), or water-injected oocytes (closed triangle) were 
preincubated in ND96 buffer (pH7.4) containing 0, 0.15, 0.5, and 1mM sodium 
nicotinate at 25oC for 60 min before urate uptake. Uptake of urate was carried 
out in ND96 buffer (pH7.4) containing 10 μM [14C]urate at 25oC for 60 min. 
Each point represents the mean ± SEM from 7-9 oocytes. Student’s t-test: 































2-3-5 Influence of preincubation time of nicotinate on the stimulation 
effect of URAT1-mediated urate uptake 
The influence of nicotinate preincubation time on stimulatory effect was 
studied after preincubation with 1 mM nicotinate for 0, 15, 30, 60 min before 
initiation of urate uptake. With an increasing preincubation time of nicotinate, 
higher stimulation of urate uptake was observed in SMCT1-URAT1 
co-expressing oocytes for up to 30 min as shown in Fig. 2-5B.  
 
 
Fig. 2-5B SMCT1-URAT1 co-expressing oocytes (closed circle), oocytes 
expressing URAT1 alone (open circle), or water-injected oocytes (closed 
triangle) were preincubated in ND96 buffer (pH7.4) containing 1 mM sodium 
nicotinate for 0, 15, 30, 60 min before urate uptake. Then, the oocytes were 
washed three times with ND96 buffer (pH7.4) and were transferred to a 24-well 
plate containing ND96 buffer (pH7.4) and 10 μM [14C]urate for the uptake study. 
Each point represents the mean ± SEM from 8-9 oocytes. Student’s t-test: 



























2-3-6 Influence of sodium ions on the stimulation effect 
To verify the mechanism of SMCT1-mediated stimulation effect, the influence 
of sodium ions and SMCT1 inhibitors was investigated. SMCT1-URAT1 
co-expressing oocytes and oocytes expressing URAT1 alone were 
preincubated in ND96 buffer with 1 mM nicotinate for 60 min in the presence or 
absence of sodium ions by replacing with N-methylglucamine. For the uptake 
of urate, oocytes were transferred to uptake medium with or without sodium 
ions. Fig. 2-6 shows that uptake of urate by SMCT1-URAT1 co-expressing 
oocytes was drastically decreased when removing sodium ions in the 
preloading condition. Meanwhile, the uptake of urate by oocytes expressing 
URAT1 alone was unchanged in the presence or absence of sodium ions.  
The apparent sodium ion dependence in preincubation medium is ascribed to 
the sodium dependent uptake of nicotinate by SMCT1. Slight, but not 
significant, effect of sodium ions during uptake of urate may be explained by 
the re-uptake of nicotinate by URAT1, which was effluxed by exchange with 
urate via URAT1.   
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Fig. 2-6. Influence of sodium ions on the stimulation of urate uptake by 
SMCT1-URAT1 co-expressing oocytes. 
SMCT1-URAT1 co-expressing oocytes (closed bar), oocytes expressing 
URAT1 alone (open bar) and water-injected oocytes (slashed bar) were 
preincubated in ND96 buffer (pH7.4) containing 1 mM nicotinate in the 
presence or absence of sodium ions. Then, the oocytes were washed three 
times with ND96 buffer or sodium free ND96 buffer (pH7.4), and were 
transferred to a 24-well plate containing ND96 buffer (pH7.4) and 10 μM 
[14C]urate for the uptake study in the presence or absence of sodium ions. 
Each point represents the mean ± SEM from 8-11 oocytes.  
 






















2-3-7 Influence of SMCT1 inhibitors on the stimulation effect 
When SMCT1-URAT1 co-expressing oocytes were preincubated with 5 mM 
butyrate or propionate, uptake of nicotinate by SMCT1-URAT1 co-expressing 
oocytes had 85% and 76% decrease, respectively (Fig. 2-7A). When oocytes 
expressing both URAT1 and SMCT1 or URAT1 alone were preincubated with 
5 mM butyrate or propionate, the stimulatory effect was also significantly 
decreased by 78% and 73%, respectively, as shown in Fig. 2-7B. Nicotinate 
uptake was comparable with that in oocytes expressing URAT1 alone, while 
the uptake was still much higher than that by water-injected control oocytes. 
Thus, these compounds are suggested to be inhibitors but not exchanged well 
with urate via URAT1 as shown in Fig. 2-3 (butyrate). Accordingly, observed 
decrease in urate uptake in the presence of butyrate and propionate may be 
due to the decreased supply of nicotinate into oocytes by inhibiting nicotinate 






Fig. 2-7 Influence of SMCT1 inhibitors on the uptake of nicotinate and 
stimulation effect on urate uptake by SMCT1-URAT1 co-expressing oocytes. 
A. Influence of butyrate and propionate on nicotinate uptake by 
SMCT1-URAT1 co-expressing oocytes (closed bar) was investigated. 
Nicotinate uptake was carried out for 60 min with 1 mM nicotinate in the 
presence or absence of 5 mM of butyrate or propionate. Open bar: uptake of 
nicotinate by water-injected oocytes. Each point represents the mean ± SEM 





























B. SMCT1-URAT1 co-expressing oocytes (closed bar), oocytes expressing 
URAT1 alone (open bar), or water-injected oocytes (slashed bar) were 
preincubated in ND96 buffer (pH7.4) with or without 1 mM nicotinate in the 
presence or absence of 5 mM of butyrate or propionate for 60 min before 
urateuptake. Then urate uptake was carried out for 60 min. Each point 




































In this study, we investigated the functional cooperation between human 
URAT1 and SMCTs in the reabsorptive transport of urate in vitro. Because 
SMCT1 and SMCT2 have similar function in the transport of monocarboxylates 
and are expressed at the tubular cells, one of them (SMCT1) was chosen to 
prove the cooperation of SMCT1 and URAT1 for urate reabsorption.  
Initially, a SMCT1-URAT1 double expressing system was established in 
Xenopus oocytes to express both SMCT1 and URAT1. A trans-stimulation 
effect of L-lactate was observed when comparing the uptake of urate by 
oocytes expressing URAT1 alone and by SMCT1-URAT1 co-expressing 
oocytes after preincubating the oocytes with L-lactate. Considering the 
possible differences in the expression level of URAT1 between URAT1-alone 
and SMCT1-URAT1 co-expressing oocytes, which may also explain apparent 
difference of urate uptake between these two types of oocytes, the effect of 
nicotinate, butyrate and L-lactate on urate uptake was studied in 
SMCT1-URAT1 co-expressing oocytes to find a better counter 
monocarboxylate to be exchanged with urate via URAT1. Since nicotinate 
showed the highest stimulation effect, we further studied the stimulation effect 
by changing the preincubation time and concentration of nicotinate. Finally, to 
confirm that URAT1 activity is stimulated by SMCT1 function, the influence of 
removing sodium ions from uptake buffer and adding SMCT1 inhibitors were 
investigated. The results of this study clearly demonstrated the functional 
cooperation of SMCT1 in urate reabsorption via URAT1.  
 
Affinities of nicotinate, L-lactate, and butyrate on SMCT1 have been reported 
in the previous studies. Km values for nicotinate, L-lactate and butyrate are 230 
μM, 81 μM, and 235 μM, respectively [81, 89]. Because they have a Km value 
around or lower than 250 μM, 1.5 mM was initially selected as the preloading 
concentration to provide enough monocarboxylate for the exchange of urate 
via URAT1. In Fig. 2-3, while SMCT1-URAT1 co-expressing oocytes were 
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preincubated with monocarboxylates, nicotinate showed higher stimulation 
effect. This phenomenon may be explained by the different affinity of nicotinate 
and lactate in the exchange with urate via URAT1 and is consistent with the 
results of a previous study in which a different stimulation effect was observed 
with direct injection of them into oocytes expressing URAT1 alone [54]. 
Physiologically, normal serum lactate concentration is around 1.5 mM, which is 
considered to provide the major driving force for URAT1. Although lactate 
concentration used in this experiment was close to normal serum lactate 
concentration, lactate showed much smaller stimulation effect than nicotinate 
under current experimental condition. The discrepancy between in vivo and in 
vitro might be explained by the reason that any monocarboxylates other than 
lactate and nicotinate may also be involved in the trans-stimulation of URAT1 
in vivo. Also, intracellular lactate concentration may be different between this 
experimental model and in vivo renal proximal tubular cell. Renal cell might 
show lower lactate concentration, so URAT1-mediated urate uptake is more 
sensitive to stimulation by SMCT1-mediated lactate transport in the renal cells 
in vivo. Although physiological relevance such as serum monocarboxylate 
concentration and stimulation of URAT1 may not be clear at present, it is clear 
that SMCT substrates increase the apparent urate uptake activity by URAT1, 
demonstrating functional cooperation of these two transporters.  
 
The accumulation of nicotinate showed concentration- and time-dependence 
and attained maximum accumulation of nicotinate at 1 mM and 60 min (Fig. 
2-5A). In accordance with such accumulation of nicotinate, urate accumulation 
in oocytes was increased with an increase of concentration and preincubation 
time of nicotinate (Fig. 2-5). These results indicated that a preincubation of 
nicotinate at 1 mM for 60 min is sufficient in the following experiments, while 
higher concentration (>1 mM) or longer preloading time (>60 min) might 
increase the nicotinate taken up by oocytes. When preincubating oocytes 
expressing URAT1 alone in ND96 buffer containing nicotinate, an increase of 
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urate uptake by oocytes expressing URAT1 alone was observed (Fig. 2-5A). 
This can be explained by the diffusion and/or carrier-mediated uptake of 
nicotinate from the uptake medium into oocytes by endogenous transporter 
which can be exchanged with urate via URAT1.  
 
As SMCT1 is a sodium dependent transporter [81, 89] but URAT is sodium 
independent, function of SMCT1 in SMCT1-URAT1 co-expressing oocytes 
should be depressed by removing sodium ions from the uptake buffer, thus 
reducing the nicotinate taken up by SMCT1-URAT1 co-expressing oocytes in 
exchange with urate and affecting the observed stimulation effect. Because the 
uptake of urate via URAT1 is not affected by sodium ions [54], removing 
sodium ions from uptake buffer should not affect the function of URAT1 in 
SMCT1-URAT1 co-expressing oocytes. As expected, by removing the sodium 
ions during the preloading of nicotinate, uptake of urate in SMCT1-URAT1 
co-expressing oocytes was greatly reduced (Fig. 2-6). The addition of butyrate 
and propionate also led to the decrease of the stimulation effect (Fig. 2-7B), 
because butyrate and propionate are inhibitors of SMCT1 and can reduce the 
accumulation of nicotinate in SMCT1-URAT1 co-expressing oocytes (Fig. 
2-7A). These results clearly indicate that the increase of urate uptake in 
SMCT1-URAT1 co-expressing oocytes was due to the exchange of nicotinate 
taken up by SMCT1 with urate and demonstrated the cooperative relationship 
between SMCT1 and URAT1 in urate reabsorption.  
 
It has been suggested that URAT1 and SMCTs can be physically linked 
through PDZK1, resulting in a possible functional relationship [90-92]. Both of 
SMCT1 and SMCT2 are known to be binding partners of PDZK1 [84]. 
Accordingly, the present study provides the functional cooperation of SMCTs 
and URAT1 in the reabsorptive transport of urate via URAT1. Expressed in 
colon, ileum, kidney and thyroid gland [93], SMCTs was recognized as a tumor 
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suppressor in the previous studies [94-99]. This study reveals the pivotal of 
SMCTs in modulation of renal urate transport.  
 
In conclusion, this is the first study providing direct evidence for the hypothesis 
that SMCTs could enhance URAT1-mediated urate uptake. Results from this 
study demonstrate the cooperative relationship of URAT1 and SMCTs and 
indicate that SMCTs may be used as a potential target for the alteration of 
renal handling of urate indirectly. Also, we should be careful in considering the 
serum uric acid level by clinically used drugs or other factors including 
diseases since change in activity of SMCTs affect reabsorptive activity of urate.  
 
Fig. 2-8 Indirect regulation of serum urate level by affecting SMCT1.  
  










Chapter 3 A putative mechanism of lowered serum 
urate level by whisky 
Abstract: 
Clinical studies show that moderate consumption of whisky results in an 
increase of renal excretion of urate into urine and a decrease of the serum 
urate level. The effects of whisky congeners on urate transporters responsible 
for the reasorptive transport of urate were examined using Xenopus oocytes 
gene-expressing system. Urate uptake by Xenopus oocytes expressing 
human URAT1 or human URATv1 was investigated in the presence or 
absence of congeners. Congeners from 12-year and 18-year whiskies showed 
an inhibitory effect of the urate uptake by URAT1 with an IC50 value of 0.084 ± 
0.011 and 0.042 ± 0.0056 mg/mL, respectively. For urate uptake by URATv1, 
congeners from 12-year whisky exhibited an inhibitory effect of about 24.4 ± 
3.0% inhibition only at 1 mg/mL. Similarly, congeners from 18-year whisky 
showed 22.5 ± 1.6% inhibition only at 1 mg/mL. There was no significant 
difference between the inhibitory effect of congeners from 12 years on 
URATv1-mediated urate uptake and that by congeners from whisky stored for 
18 years. At lower concentrations, there was no inhibitory effect observed for 
both of the congeners. Results of this study suggested that decreased serum 







Lifestyle and dietary factors are closely related to human health. Daily 
exposure of food is inevitable for all human beings. Influence of different kinds 
of food and beverage on human health has been realized since ancient times. 
At present, food therapy has been regarded as one of the most important 
approaches of Traditional Chinese Medicine for the cure or prevention of a 
number of diseases [100]. With the development of modern science, an 
increasing number of scientific evidences and reports have emerged in recent 
years illustrating the mechanisms of the impact of food and beverage on 
human health and providing new evidences at the same time.  
 
Urate is the final product of purine metabolism in humans. Because humans 
lack urate oxidase, urate cannot undergo further oxidation reaction to form 
allantoin, a more soluble compound. Serum urate level is maintained by the 
generation and excretion of urate. Purine intake from food is an important 
source of serum urate accounting for approximately one third of daily urate 
load [101]. Intake of purine-rich food has been associated with incident of 
hyperuricemia and gout attack [102-103]. Acute intake of purine-rich food can 
raise the risk of recurrent gout attack as high as five fold in patients suffering 
from gout [104]. It is also found that impact of purine from animal sources on 
recurrent gout attack was higher than that from plant sources. Thus, intake of 
low purine food and reduced consumption of animal-source food have been 
suggested in the prevention and treatment of hyperuricemia and gout 
[105-107].  
 
Serum urate level is related to alcohol and beverage intake as well. Habitual 
intake of alcoholic beverages and hyperuricemia has been associated in many 
reports. In a recent study carried out in Japanese men, alcohol intake and risk 
of the incident hyperuricemia are correlated at a dose dependent manner. 
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Alcohol intake is responsible for 21.6% of hyperuricemia occurrence in 
Japanese men [108]. Alcohol consumption can also increase the risk for gout 
attack in men [109]. For the relationship between alcohol consumption and 
high urate level, two putative mechanisms have been proposed. One is that 
alcohol intake can increase lactate level during alcohol oxidation and lactate is 
an important substrate of sodium-coupled monocarboxylate transporters 
(SMCTs) for the exchange of urate via urate transporter 1 (URAT1). SMCTs 
have functional cooperative relationship with URAT1 as is demonstrated in 
Chapter 2 and has been reported in our previous study [110]. Increased lactate 
may enhance the reabsorptive transport of urate through URAT1. The other 
might be due to the increased adenosine triphosphate (ATP) degradation to 
adenosine monophosphate (AMP) during alcohol metabolism [111-113]. 
Because urate is synthesized from adenosine, the production of urate will be 
enhanced after alcohol intake.  
 
Consumption of alcoholic beverages has been a feature of many cultures 
throughout the world since ancient times, and especially in some Asian 
countries, is often associated with social gatherings. Many studies have shown 
that regular alcohol consumption is a risk factor for hyperuricemia and gout 
attack, though moderate consumption of some kinds of alcoholic beverages 
may provide health benefits. For example, moderate red wine drinking may 
help to reduce the risk of coronary heart disease [114]. Such effect might be 
attributed to the nonvolatile substances (called congeners) generated during 
brewing maturation processes. It has been reported that congeners contained 
in whisky exhibit diverse biological activities including protection of the 
gastrointestinal tracts, inhibition of melanogenesis and suppression of NO 
production [115-118]. Recent clinical studies show that consumption of 
whiskey results in an increase of renal excretion of urate as well as a decrease 
of the serum urate level (SUA) [119], although the mechanism remains to be 
determined. Therefore, understanding effect of the congeners on alteration in 
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urate reabsorption may help us to find the molecular details of decreased SUA 
after whisky consumption.  
 
In order to delineate the mechanism by which serum urate level is reduced 
after whisky consumption presumably by certain congeners, it is essential to 
understand how whisky congener is involved in alteration in serum urate level. 
Urate is poorly hydrophilic to permeate the membranes of proximal tubular 
cells, thus membrane transporters play a pivotal role in its reabsorptive and 
secretory transcelluar transport and maintain SUA [120]. Till now, a number of 
membrane transporters involved in urate transport have been identified 
including organic anion transporter family members (OATs) and breast cancer 
resistance protein (BCRP) [54]. Among these transporters, urate transporter 1 
(URAT1/SLC22A12), which is a member of OATs, is localized on the apical 
side of renal proximal tubular cells and has been characterized as a 
transporter mainly responsible for renal reabsorption of urate from lumen into 
blood [54]. Since kidney handles approximately 70% of urate in the body, renal 
urate transporters are of great significance. Currently, URAT1 has already 
been a target for the development of novel anti-hyperuricemia compounds. On 
the basolateral side of renal proximal tubule, a voltage-driven urate transporter 
(URATv1/ SLC2A9) functions as a urate transporter mediating the urate 
transport from proximal tubular cell into blood [64]. Cooperative role of URAT1 
and URATv1 in renal reabsorption of urate has been demonstrated by the 
previous study conducted in our laboratory [121]. In order to explain the 
phenomenon of decreased SUA after drinking whisky, in the present study we 
examined whether whisky congeners have any inhibitory effect on URAT1 and 
URATv1 mediated reabsorptive transport of urate (putative mechanism is 




Fig. 3-1 Hypothesized model of congener’s effect on renal urate reabsorptive 
transport. Whisky congeners inhibit URAT1and URATv1-mediated urate 
reabsorptive transport, reducing the serum urate level.  
  








3-2 Materials and Methods 
3-2-1 Materials 
[14C]Urate (1.96 TBq/mol) was purchased from Moravek Biochemicals, Inc. 
(Brea, CA). Congeners from 12 and 18-year old whiskies were supplied by 
Suntory Holdings (Osaka, Japan). Clearsol-I was the product of Nacalai 
Tesque (Kyoto, Japan). All other reagents were of analytical grade. 
 
3-2-2 Preparation of URAT1 and URATv1 cRNA 
Human URAT1 and URATv1 cRNA were in vitro transcribed and Xenopus 
oocytes expressing these transporters are prepared as previously described in 
Chapter 2-2. The whole study was approved by the Institutional Animal Care 
and Use Committee of Kanazawa University.  
 
3-2-3 Uptake study by Xenopus laevis oocyte 
As for uptake of urate by oocytes expressing URAT1 or URATv1, oocytes were 
treated as previously described in Chapter 2-2. Uptake of [14C]urate (20 μM) 
by oocytes expressing URAT1 was carried out for 60 min at 25 oC in pH7.4 ND 
96 buffer free of Cl- ions. [14C]Urate uptake by oocytes expressing URATv1 
was performed for 60 min in ND96 buffer not containing Na+ ions. At the end of 
uptake experiment, oocytes were washed three times with ice-cold uptake 
buffer, and each oocyte was lysed in 5% sodium dodecyl sulfate solution (50 
μL) to quantify radioactivity on a liquid scintillation counter (LSC-5100, Aloka, 
Tokyo). 
 
pH7.4 ND96 buffer free of Cl- ions: 
96 mM sodium gluconate 
2 mM potassium gluconate 
1 mM magnesium gluconate  
1.8 mM calcium gluconate  
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5 mM HEPES 
Adjust pH to 7.4. 
 
ND96 buffer not containing Na+ ions 
98 mM KCl 
1 mM MgCl2 
1.8 mM CaCl2 
5 mM HEPES 
Adjust pH to 7.4. 
 
3-2-4 Data Analysis 
Inhibitory effect of congeners on urate uptake was calculated by KaleidaGraph 
4.0 (Synergy Software, Reading, PA) with following equation:  
% of control = 100 × IC50/(IC50 + I),  
in which IC50 is the 50% inhibitory concentration; 
I is the concentration of the congeners used in the experiment. 
All data were expressed as mean ± SEM. Statistical significance was analyzed 






3-3 Results  
3-3-1 Effect of whisky congeners on URAT1 mediated urate uptake 
Influence of whisky congeners on URAT1- and URATv1-mediated urate uptake 
was studied to delineate their potentials to lower SUA after whisky 
consumption. Congeners from 12 and 18-year old whiskies were tested for 
their effect on URAT1-mediated [14C]urate uptake at a concentration range 
from 0.01 to 0.5 mg/mL, and 0.002 mg/mL to 0.5 mg/mL, respectively. Both 
congeners inhibited URAT1-mediated urate uptake in a 
concentration-dependent manner (Fig. 3-2 A and B). IC50 values for congeners 
from 12 and 18-year old whiskies were estimated at 0.084 ± 0.011 (Fig. 3-2A) 







Fig. 3-2 Inhibitory effect of 12 (A) and 18-year (B) old whisky congeners on 
URAT1-mediated urate uptake. Each point represents the mean ± SEM from 









































3-3-2 Effect of whisky congeners on URATv1 mediated urate uptake 
To determine whether congeners from 12 and 18-year old whiskies have any 
inhibitory effect on URATv1-mediated urate uptake, the congeners were tested 
for their inhibitory effects on uptake of urate by oocytes expressing URATv1. 
Figure 3-3A shows that congeners from 12-year old whisky reduced the 
uptake by 24.4 ± 3.0% at 1mg/mL. Similarly, congeners from 18-year old 
whisky showed 22.5 ± 1.6% inhibition at 1mg/mL (Fig. 3-3B). No significant 
difference was found between the effects of the congeners from 12 and 
18-year old whiskies at 1 mg/mL. At lower concentrations (0.1 mg/mL and 0.01 
mg/mL), both congeners showed no inhibitory effect on URATv1-mediated 








Figure 3-3 Inhibitory effect of 12 (A) and 18-year (B) old whisky congeners on 
URATv1-mediated urate uptake. Each point represents the mean ± SEM from 









































3-4 Discussion  
In the present study, we aimed at investigating the possible mechanism of 
lowered serum urate level after whisky consumption. Due to the important role 
of URAT1 and URATv1 in regulating serum urate level, we investigated the 
effect of whisky congeners on these urate transporters. Both 12-year and 
18-year congeners showed inhibitory effect on URAT1 mediated urate uptake 
(Fig. 3-2). Interestingly, 18-year old whisky congener exhibited stronger 
inhibitory effect on URAT1-mediated urate uptake compared with that by 
12-year old one. Spirit maturation is an important process responsible for the 
quality, flavor, color and taste of whisky. During the long maturation time, many 
substances are generated including aromatic aldehydes, phenols and acids 
[122-123], either by migration of oak constituents or by maturation of spirit. It 
has been reported that 18-year congener has higher contents of polyphenolic 
compounds compared with 12-year congener, such as gallic acid, ellagic acid 
and lyoniresinol [124]. Because content of congeners in whisky is associated 
with maturation time [123], longer maturation of whisky in oak casks might 
generate more substances, resulting in more enriched congeners, where 
higher yield of active ingredients may be responsible for greater inhibition of 
URAT1. This might explain observed stronger effect of congener from18-year 
old whisky. 
 
Congeners showed inhibitory effect on URATv1-mediated urate uptake at 1 
mg/mL (Fig. 3-3). At lower concentration, congeners seem to have no 
inhibitory effect on URATv1-mediate urate uptake. Because 1 mg/mL is close 
to the original concentration of congeners in whisky, these congeners are 
unlikely to reach such high concentration in vivo. Therefore, the inhibition of 
URATv1 mediated urate uptake by whisky congeners is not likely to exist after 




In conclusion, the current study shows that congeners from whiskies matured 
for 12 and 18 years can inhibit URAT1 and URATv1 mediated urate uptake 
under experimental conditions employed in the present study. Considering the 
concentration of congeners in vivo, inhibition of URAT1 by congeners more 
likely contributes to reduce SUA after whisky consumption (Fig. 3-4). 
 
Fig. 3-4 Proposed mechanism for lowered serum urate level after whisky 
consumption. Whisky congeners may reduce serum urate level by inhibition of 
URAT1-mediated urate reabsorptive transport.   







Chapter 4 Indoxyl sulfate upregulates BCRP 
expression in intestinal cell line  
Abstract 
In the state of chronic renal disease (CKD), renal function is greatly reduced. 
However, the rise of serum urate level is not much, compared with other 
solutes. Compensatory increased non-renal urate excretion might be 
contributing to explain this phenomenon. Intestinal BCRP is significantly 
involved in controlling serum uric acid level and previous study shows that 
Bcrp expression is increased in CKD rats, while it is not known whether such 
an increase of Bcrp affect intestinal secretion of urate or not. In this report, we 
examined whether indoxyl sulfate (IS) is involved in the upregulation of BCRP 
in intestine at CKD state. After exposure to IS, mRNA level, and protein level of 
BCRP in Caco-2 cells were assayed by real-time PCR and flow cytometry, 
respectively. BCRP mRNA level was increased by exposure to IS for 24 h at a 
concentration dependent manner and reach steady state at 0.2 mM, a clinical 
relevant concentration. BCRP expression in membrane fraction was also 
increased by 1.8 folds after treatment with 0.2 mM for three days. 
Basolateral-to-apical  transport of urate in Caco-2 cells had 22% increase 
after IS treatment. Intracellular accumulation of selective substrate of BCRP, 
pheophorbide a, was also decreased by 22% after IS treatment. IS was also 
observed to increase BCRP mRNA expression in LS180 cells and HepG2 cells, 
which are enterocytes- and hepatocytes-model cell lines, respectively. 
However, no protein was expressed in membrane fraction of LS180 cells. 
BCRP protein expression in membrane fraction of HepG2 cells was increased 
after IS treatment, whereas no function of BCRP was observed in HepG2 cells. 
Results indicate that indoxyl sulfate might be involved in the up-regulation of 






Urate is the final product of purine metabolism in humans. Due to the loss of 
uricase in the evolution of human being, urate cannot be degraded into 
allantoin which is more soluble than urate. In humans, urate primarily excretes 
through kidney and intestine. Traditionally, kidney is regarded as an important 
organ in the excretion of urate. It has been revealed that almost two thirds of 
urate daily produced is excreted through kidney [125-126]. In many cases, 
reduced function of kidney has been associated with gout and hyperuricemia 
[127-129]. However, the rise of serum urate level is not high compared with 
many other solutes which may be excreted by kidney at chronic kidney failure 
state, a state during which renal function is greatly reduced. This might be 
explained by a compensatory increase of intestinal urate excretion, as is 
reported by Vaziri et al. who observed the increase of intestinal urate excretion 
in CRF rats [130]. Recent genome-wide association studies show that breast 
cancer resistance protein (BCRP, encoded by ABCG2), which is highly 
expressed in intestine, is associated with the cause of gout and hyperuricemia 
[131-137]. Urate was identified as the substrate of BCRP by efflux experiments 
using oocytes expressing ABCG2 gene and decreased intestinal urate 
excretion was observed in Bcrp knockout mice [138]. Yano et al. reported that 
BCRP expression was increased in the intestine of CRF rats [139].  
 
Indoxyl sulfate (IS), a derivative of diary protein, is generated in intestine by 
bacteria-mediated protein-derived tryptophan metabolism and mainly excreted 
by kidney [140-141]. Members from OAT family, OAT1 and OAT3, located at 
renal proximal tubule are responsible for the excretion of IS [142-146]. At 
normal state, serum indoxyl sulfate concentration is about 2.5 μM in humans 
[147-148]. In patients with chronic kidney failure, serum indoxyl sulfate 
concentration can be increased to as much as 210 μM [147-148]. Indoxyl 
sulfate exhibits numerous biological functions. It induces oxidative stress in 
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many kinds of cells, inhibits NO production, and has an inhibitory effect on 
endothelial proliferation [149-153]. It also stimulates glomerular sclerosis and 
plays a pivotal role in the progression of kidney failure [154-155]. Recent 
reports indicate that indoxyl sulfate exhibits as a potent endogenous agonist 
for the aryl hydrocarbon receptor (AhR) [156], a transcriptional activator of 
BCRP [157]. In the present study, we investigated whether indoxyl sulfate is 






4-2 Materials and Methods 
4-2-1 Chemicals and reagents 
Indoxyl sulfate (potassium salt) was purchased from Nacalai Tesque (Kyoto, 
Japan). 3-Methylchoranthrene (3-MC) and Ko143 were from Sigma-Aldrich (St. 
Louis, MO). Pheophorbide a (PhA) and albumin from bovine serum (Fraction 
V) were the products of Wako Pure Chemical Industries (Osaka, Japan). 
Fluorescein isothiocyanate (FITC) labeled 5D3 antibody (anti-BCRP) and 
FITC-labeled isotype control (mouse IgG2b) were purchased from BioLegend 
(San Diego, CA). [14C]Urate (1.96 TBq/mol) was purchased from Moravek 
Biochemicals, Inc. (Brea, CA). All other reagents were of analytical grade. 
 
4-2-2 Cell culture 
Caco-2 cells, HepG2 cells and LS180 cells obtained from the American Type 
Culture Collection (Rockville, MD) were cultured at 37 oC in Dulbecco’ s 
modified Eagle’s medium (D-MEM; Wako Pure Chemical Industries, Osaka, 
Japan) with L-Glutamine and phenol red, supplemented with 10% (v/v) fetal 
bovine serum (FBS; Hyclone, Thermo Scientific, Logan, UT, USA), 1% (v/v) 
MEM nonessential amino acids (Wako Pure Chemical Industries, Osaka, 
Japan), 100 units/mL penicillin, and 100 μg/mL streptomycin. 
 
4-2-3 Total RNA isolation and real time PCR 
Total RNA from the cells was extracted by the addition of Isogen (Wako Pure 
Chemical Industries, Osaka, Japan) according to the manufacturer’s 
operational manual. Briefly, after the removing the culture medium, cells were 
washed by pH7.4 phosphate buffered saline (PBS) twice. Isogen was then 
added into each well and samples of each well were transferred into a 1.5 mL 
tube after 5 min. Chloroform was added to purify RNA and isopropanol was 
used to precipitate RNA. The concentration of total RNA was determined by 
UV method on an Eppeendorf BioPhotometer (Eppendorf, Hamburg, 
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Germany). 1 μg of total RNA was used for the synthesis of cDNAs with a High 
Capacity cDNA Reverse Transcription Kit (Invitrogen, Carlsbad, CA). RNA was 
mixed with 2 μL 10xRT Random Primers supplemented with purified water to 
10 μL and was denatured at 65 oC for 7min.  
Reverse transcription reactions were prepared by mixing denatured RNA with 
following components:   
10xRT buffer             2.0 L 
100 mM dNTP Mix        0.8 L 
Reverse Transcriptase    1.0 L 
Pure water               6.2 L 
Total:                    10 L 
 
Reverse transcription was then carried out on GeneAmp PCR System 2700 
(Applied Biosystems, Foster City, CA, USA) using following program:  
Step1: 25°C 10min 
Step2: 37°C 120min 
Step3: 85°C 5 s 
Step4: 4°C ∞ 
Real-time PCR 
For real-time PCR reaction was performed using a Stratagene Mx3000P 
real-time PCR system (Agilent Technologies, La Jolla, CA, USA). Master Mix 
was made by following method:  
primer mix (each 10 µM)        0.75 μL 
2 X SYBRGS                7.5 µL 
ROX dye                         0.2 µL 
purified water              5.55 μL 
total                  14 μL 
Then 14 μL of Master Mix was transferred into a reaction tube. 1μL of reverse 
transcription product was added into the reaction tube and mixed.  
PCR reaction was cycled as follows: 
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95°C 10min    x1   
94°C (10s)  
55°C (10s)    x45 cycles 
72°C (15s)  
Cool to 4°C 
 
1 μL of the reverse transcription product was mixed with 0.75 μL of 10 μM 
primer mix, 0.2 μL ROX reference dye (Agilent Technologies), 5.55 μL of 
purified water and 7.5 μL of 2X Brilliant III Ultra-Fast SYBR® Green QRT-PCR 
Master Mix (Agilent Technologies) to perform the real-time PCR using a 
Stratagene Mx3000P real-time PCR system (Agilent Technologies, 
La Jolla, CA, USA). The PCR circling conditions were as follows: denaturation 
at 95 oC for 10 min; 45 cycles of 94 °C for 10 s, 55 °C for 10 s, 72 °C for 10 s; 
and 1 cycle of 95 oC for 1 min, 55 oC for 30 s, 95 oC for 30 s. 
 
Data were analyzed by MxPro QPCR software (Version 4.10, Stratagene).  
∆∆Ct method was used to calculate the relative gene expression of BCRP and 
the expression of the housekeeping gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) was used as the internal control. 
Sequences of the primers used for BCRP and HPRT detection was as follows. 
For BCRP (product size 187 bp): 5′-GTTTCAGCCGTGGAAC-3′ (sense); 
5′-CTGCCTTTGGCTTCAAT-3′ (antisense). For HRPT (product size 94 bp): 
5′-TGACACTGGCAAAACAATGCA-3′ (sense); 
5′-GGTCCTTTTCACCAGCAAGCT-3′ (antisense).  
 
4-2-4 Expression of BCRP in membrane fraction 
Expression of BCRP in membrane fraction was examined by flow cytometer on 
a BD FACScan™ flow cytometry system (BD Biosciences, Mountain View, CA). 
Cells were trypsinized by 0.1% trypsin (BD Biosciences, Sparks, MD) at room 
temperature for up to 5 mins. Cell pallet was obtained by centrifuging at 200 g 
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for 5min. Cells were resuspended in 2% BSA/PBS and kept on ice for 30 min. 
After that, cells were incubated with FITC-labeled 5D3 antibody or 
FITC-labeled isotype control (mouse IgG2b) at 14°C for 3h in the dark at the 
concentration of 1:10 in 2% BSA/PBS solution. After immunofluorescent 
staining, cells were washed by PBS and kept in dark on ice until analysis. 
Surface expression of BCRP was calculated by comparing the fluorescence 
intensity (Geo mean value) of the cells stained by 5D3 and the isotype control.  
 
4-2-5 Intracellular accumulation of PhA in Caco-2 cells 
Intracellular accumulation of PhA in Caco-2 cells was examined by flow 
cytometeron a BD FACScan™ flow cytometry system (BD Biosciences, 
Mountain View, CA). Caco-2 cells totally cultured for two weeks were 
trypsinized by 0.1% trypsin at room temperature for up to 5 min. Cell pallet was 
obtained by centrifuging at 200 g for 5 min. Cells were re-suspended in culture 
medium containing 5 μM PhA with or without 1 μM Ko143 and incubated at 
37°C for 60 min in dark. After that, cells were centrifuged at 200g for 5 min to 
get the pellet. The resultant cell pellet was washed by 1 mL PBS and 
re-suspended in 0.5 mL PBS. Samples were kept in dark on ice and 
subsequently analyzed by flow cytometry. Intracellular accumulation of PhA 
was calculated by comparing the fluorescence intensity (Geo mean value) of 
the cells with or without the addition of Ko143 during the uptake.  
 
4-2-6 Transcellular urate transport in Caco-2 cells 
To investigate whether IS treatment has any effect on the transcellular urate 
transport in Caco-2 cells, Caco-2 cells were treated for 3 days with 0.2 mM IS 
on both apical side and basolateral side before the experiment, totally cultured 
for three weeks on Transwell filter membrane inserts (BD Falcon, surface area 
0.9 cm2 and pore size 3 mm) after subculture at a density of 6.4X10-4/well. 
Then, transcellular urate transport study was carried out according to the 
method previously described [52]. The apparent permeability (Papp, cm/sec) of 
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[14C]urate across the cell monolayer from basolateral side to apical side was 
calculated by following equation: 
Pୟ୮୮ ൌ ୢ୕ୢ୲ ∗
ଵ
୅େ଴  
In which Q is the amount of [14C]urate transported over time t, C0 is the initial 










4-3-1 mRNA expression of BCRP in Caco-2 cells 
mRNA expression of BCRP in Caco-2 cells was firstly examined by real-time 
PCR. Caco-2 cells were seeded on a 24 well plate at a density of 1x105 
cells/well and were exposed to 1.0 mM indoxyl sulfate for 24 h before the 
experiment (totally cultured for 2 weeks) after subculture. Ten μM 3-MC was 
used as positive control for induction of BCRP. mRNA expression of BCRP in 
Caco-2 cells was increased by approximately 4 fold after the exposure to 
indoxyl sulfate and 10 μM 3-MC (Fig. 4-1A). IS also showed an induction of 
expression of Bcrp mRNA in a concentration dependent manner (Fig. 4-1B). It 
reached steady state at 0.2 mM which was clinically relevant concentration at 
disease state. Thus, 0.2 mM of IS treatment was used as further studies.  
 
Fig. 4-1 mRNA level of BCRP in Caco-2 cells treated with IS. (A) After 24h 
exposure, BCRP mRNA level was increased approximately 4 folds by IS and 














   























(B) After 24h exposure, BCRP mRNA level was increased at a concentration 





































4-3-2 Protein expression of BCRP in membrane fraction of Caco-2 cells 
Caco-2 cells were seeded on a 24 well plate at a density of 1x105 cells/well 
and were exposed to 0.2 mM indoxyl sulfate for 1, 3, and 5 days before the 
experiment, with totally cultured for two weeks after subculture. BCRP 
expression in membrane fraction of Caco-2 cells was subsequently examined 
using flow cytometry method with FITC-conjugated 5D3 as the antibody 
against BCRP protein. Expression of BCRP in membrane fraction of Caco-2 
cells showed a time-dependent incresae after treatment with 0.2 mM. After 
three days’ exposure, BCRP expression reached steady state by increasing 
1.8 folds compared with non-treated control group (Fig. 4-2). Longer exposure 
time could not result in higher BCRP expression at membrane fraction.  
 
 
Fig. 4-2 Time dependent increase of BCRP protein after 0.2 mM IS treatment. 
FITC-conjugated 5D3 was used as the antibody against BCRP protein. 
FITC-conjugated mouse IgG2b was used as isotype control. After treated for 
three days, BCRP expression in membrane fraction reached steady state. 
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4-3-3 Transcellular urate transport in Caco-2 cells treated with IS 
Transcellular urate transport was carried out to investigate whether IS 
treatment has any effect on the function of cells. After exposure the cells to 0.2 
mM IS for three days before the transport study, urate transport increased by 
22%, compared with the non-treated control group (Fig. 4-3).  
 
 
Fig. 4-3 Transcellular transport of urate in Caco-2 cells. After treated with 0.2 
mM IS for three days, permeability of urate in Caco-2 cells has 22% increase 
compared with that of the non-treated control group. Data represent as mean ± 























4-3-4 Intracellular accumulation of PhA in Caco-2 cells after IS treatment 
To investigate whether mRNA and protein increase of BCRP can result in any 
functional increase of BCRP, intracellular accumulation of PhA, a typical BCRP 
substrate, was studied by flow cytometry method. Function of BCRP in Caco-2 
cells cultured for two weeks was observed as shown in Fig.4-4, due to the 
reduced intracellular accumulation of PhA in the absence of 1 μM Ko143. In 
control group, intracellular accumulation of PhA was 88.7% of that in the 
presence of Ko143. After IS treatment, intracellular accumulation of PhA 
decreased from 88.7% to 66.7% of that in the presence of Ko143, which 
indicated that function of BCRP was increased after IS treatment.  
 
 
Fig. 4-4 Intracellular accumulation of PhA in Caco-2 cells. Caco-2 cells were 
treated with IS for 3 days before the experiment (totally cultured for two weeks). 
Intracellular accumulation of PhA reduced to from 88.7% to 66.7% compared 
























4-3-5 Effect of IS on BCRP mRNA expression in LS180 cells 
We further examined whether the induction of BCRP by IS exists in other 
intestinal cell lines. LS180 cells were exposed to IS at concentrations from 
0.1-1mM for 48 hours after subcultured on a 24 well plate at a density of 1x105 
cells/well. Total RNA was subsequently extracted and mRNA level of BCRP 
was examined by real-time PCR. IS showed an increase in BCRP mRNA level 
in a concentration-dependent manner. After treatment with 0.2 mM IS for 48 
hours, BCRP mRNA expression was increased by 122 folds (Fig. 4-5).  
 
Fig. 4-5 Effect of IS on BCRP mRNA expression in LS180 cells. LS180 cells 
were treated with 0.2 mM IS for 48h after subculture. BCRP mRNA expression 































4-3-6 Protein expression of BCRP in membrane fraction of LS180 cells 
BCPR expression in membrane fraction of LS180 cells was examined after 
treatment with 0.2 mM IS for 48 h after subculture at a density of 1x105 
cells/well in a 24-well plate. BCRP expression in membrane fraction of LS180 
cells was subsequently examined using flow cytometry method with 
FITC-conjugated 5D3 as the antibody against BCRP protein and with 
FITC-conjugated mouse IgG2b as isotype control. Expression of BCRP in 
membrane fraction of LS180 cells has no significant change after IS treatment 
(Fig. 4-6).  
 
Fig. 4-6 Protein expression of BCRP in membrane fraction of LS180 cells. 
LS180 cells was examined after treatment with 0.2 mM IS for 48 h and BCRP 
protein expression in membrane fraction was subsequently examined by flow 
cytometry after staining with FITC-conjugated 5D3 antibody. FITC-conjugated 
mouse IgG2b was used as isotype control. No significant change of membrane 
BCRP protein expression was observed after IS treatment. Data represent as 




























4-3-7 Effect of IS on BCRP mRNA expression in HepG-2 cells  
Because BCRP is also reported to be expressed in liver which might be 
involved in non-renal urate excretion, we also examined whether IS has any 
effect on BCRP expression in liver cells. HepG2 cells were exposed to IS at 
concentrations from 0.1-1 mM for 24 h after subculture on a 24 well plate at a 
density of 1x105 cells/well for 7 h. BCRP mRNA level was subsequently 
examined. BCRP mRNA level in HepG2 cells was increased in a concentration 
dependent manner both for IS and 3-MC induction (Fig. 4-7).  
 
 
Fig. 4-7 Effect of IS on mRNA expression of BCRP in HepG-2 cells. After 24 h 
IS treatment, BCRP mRNA level in HepG2 cells was increased in a 
concentration dependent manner from 0.1 to 1 mM. 3-MC also increased 
BCRP mRNA level in a concentration dependent manner from 1 to 10 μM. 






































4-3-8 Protein expression of BCRP in membrane fraction of HepG2 cells 
BCPR expression in membrane fraction of HepG2 cells was examined after 
treatment with 0.2 mM IS for 48 h after subculture at a density of 1x105 
cells/well in a 24-well plate. BCRP expression in membrane fraction of HepG2 
cells was subsequently examined using flow cytometry method with 
FITC-conjugated 5D3 as the antibody and FITC-conjugated mouse IgG2b was 
used as isotype control. Expression of BCRP in membrane fraction of HepG2 
cells has 3-fold increase after IS treatment (Fig. 4-8).  
 
Fig. 4-8 Protein expression of BCRP in membrane fraction of HepG2 cells. 
BCRP expression in membrane fraction of HepG2 cells was examined after 
treatment with 0.2 mM IS for 48 h and BCRP protein expression in membrane 
fraction was subsequently examined by flow cytometry after staining with 
FITC-conjugated 5D3 antibody. FITC-conjugated mouse IgG2b was used as 
isotype control. After IS treatment, BCRP membrane expression had 3-fold 




















4-3-9 Intracellular accumulation of PhA in HepG2 cells treated with IS 
Due to the increase of membrane BCRP protein observed in HepG2 cells after 
IS treatment, we next investigated whether mRNA and protein increase of 
BCRP can result in any functional increase of BCRP in HepG2 cells. 
Intracellular accumulation of PhA was studied by flow cytometry method. 
Ko143 seems to have no effect on intracellular accumulation of PhA in control 
cells (Fig. 4-9). Similar phenomenon was observed in cells after IS treatment 
(Fig. 4-9). This indicated that BCRP expression might be too low to show 
some function in HepG2 cells.  
 
Fig. 4-9 Intracellular accumulation of PhA in HepG2 cells after IS treatment. 
HepG2 cells was examined after treatment with 0.2 mM IS for 48 h and 
Intracellular accumulation of PhA was subsequently examined by flow 
cytometry after incubation with 5 μM PhA for 60 min. Data represent as mean ± 



















Past decades have witnessed a great increase in the prevalence of CKD. The 
cost used for the treatment of CKD has been steadily increasing throughout 
the world. To investigate the physiological change at CKD state is crucial for 
the better understanding of the mechanism of the disease, providing essential 
knowledge for the treatment of CKD. It has been reported that intestinal urate 
excretion was increased at CKD state. In the present study, we depicted the 
possible role of IS, a well-recognized uremic toxin, in the induction of BCRP at 
CKD state as a compensation of the body to the decreased renal function.  
 
Initially, Caco-2 cells were selected as an intestinal epithelial model cell line to 
examine the effect of IS on BCRP expression. Both mRNA level and 
membrane protein level of BCRP were increased after treatment of IS at a 
clinically relevant concentration. We next investigated the functional change of 
BCRP after IS treatment in Caco-2 cells. Accumulation of PhA, a probe 
compound for the evaluation of BCRP function, was decreased after IS 
treatment. Similarly, basolateral to apical directed urate transport was 
increased by 22% after IS treatment (Fig. 4-3). The increase of urate transport 
after exposure to IS was relatively small (22%) compared with the increase in 
mRNA level (3 folds) and membrane fraction protein expression (1.8 folds). 
This might be attributed to several reasons. At first, transporters expressed at 
the basolateral side of Caco-2 cells may not be efficient in transporting urate 
from basolateral side into Caco-2 cells. Secondly, influx transporters on the 
apical side may be also upregulated by IS, reducing net urate efflux by Caco-2 
cells. Or other transporters than BCRP, that is not affected by IS is also 
contributing to this transport.  
 
In LS180 cells, BCRP mRNA level was quite low as is reported by previous 
study, over 100-fold lower than that in Caco-2 cells [158]. After IS treatment, 
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BCRP mRNA level was increased by 122 fold as is shown in Fig.4-5. However, 
no protein expression was detected in membrane fraction of LS180 cells 
before and after IS treatment. This might be due to the lack of other 
transcriptional factors for BCRP protein expression in LS180 cells.  
 
In HepG2 cells, both BCRP mRNA level and membrane protein expression 
were increased after IS treatment (Fig. 4-7 and Fig. 4-8). However, no 
functional increase was observed (Fig. 4-9). BCRP seems to have no function 
in HepG2 cells. Because Ko143 could not increase the intracellular 
accumulation of PhA in HepG2 cells. BCRP protein expression in HepG2 cells 
might be too low and it is difficult to detect its function under current 
experimental conditions.  
 
BCRP expression can be regulated by many factors. For example, AhR has 
shown the inductive effect on BCRP expression in human intestinal, liver, and 
mammary carcinoma cells and in primary colonocytes and hepatocytes [157]. 
Also, peroxisome proliferator-activated receptor-α agonist can up-regulate the 
expression of Bcrp in mice intestine [159]. IS might stimulate AhR to 
up-regulate BCRP expression, because it has been reported as a potent AhR 
agonist [156]. In the present study, 3-MC, an AhR agonist was used as positive 
control and it exhibited up-regulatory effect on BCRP expression (Fig. 4-1A 
and Fig. 4-7). This indicated that stimulation of AhR might be involved in the 
upregulation of BCRP by IS. However, other stimulation factors than AhR 
might also exist. Thus, further studies are still needed to illustrate the 
mechanism of the phenomenon observed in the present study.  
 
Results from the present study show that BCRP expression and transcellular 
urate transport can be enhanced by IS at clinically relevant concentration. IS 
might be involved in the upregulation of intestinal BCRP expression at CKD 
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state and responsible for the compensatory increase of non-renal urate 




Chapter 5 Conclusion 
Since the discovery of URAT1 in 2002, many compounds which can lower 
serum urate level have been identified as URAT1 inhibitors. These compounds 
can influence serum urate level in a direct manner by blocking URAT1 directly. 
In Chapter 2, a cooperative relationship of SMCT1 and URAT1 was proved. 
This indicates that SMCT1 is also involved in renal urate transport, but it works 
in an indirect manner in the regulation of serum urate level. Thus, SMCT1 is 
possibly to be used as a new target for the development of novel compounds 
to regulate serum urate level in an indirect manner. This kind of compounds to 
be developed might be used alone or in combination with other URAT1 
inhibitors to regulate serum urate level, increasing the efficiency of current 
compounds or reducing the side effect of current compounds.  
 
In Chapter 3, interaction of whisky congeners with urate transporters was 
studied as a new rationale for their effect on lowering serum urate level. 
Inhibition of URAT1 by congeners might be involved in the lowered serum 
urate level after whisky consumption. Due to the complexity of whisky 
congeners, further studies are still needed to identify what kind of compounds 
are more likely to be responsible for the inhibition of URAT1.    
 
Chapter 4 focused on efflux urate transporter and investigated the change of 
BCRP at disease state. It shows that indoxyl sulfate, a model uremic toxin, 
might be involved in the regulation of BCRP and contributes to the increased 
compensatory non-renal urate excretion. The molecular mechanism of this 
phenomenon still needs to be investigated. 
 
In conclusion, this thesis shows that serum urate level can be regulated by 
directly or indirectly influencing urate transporters and humans have a 
self-compensatory mechanism to regulate serum urate level at disease state 
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by modulation of urate transporters. The results of this thesis indicate that 
transporters involved in urate transport can be used as targets for developing 
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